Skip to main
KRYS

Krystal Biotech (KRYS) P/E Ratio

P/E Ratio as of Feb 2, 2026: 42.34

Average41.06
Median41.84
Minimum36.70
Maximum43.79
42.34
5.31 (14.34%)past month
The P/E ratio for Krystal Biotech (KRYS) is 42.34 as of Feb 2, 2026. This represents a increase of 6.92% compared to its 12-month average P/E ratio of 39.6. A higher P/E ratio suggests that investors expect strong future earnings growth, while a lower P/E ratio may indicate a potentially undervalued stock or slowing growth.

Krystal Biotech P/E Ratio Formula = Stock Price ÷ Earnings Per Share (EPS)

Krystal Biotech’s P/E ratio represents the valuation of the company based on its earnings. It’s calculated by dividing the company’s latest stock price by its diluted earnings per share (EPS) over the past 12 months. The P/E ratio helps investors assess how much they are paying for each dollar of earnings, offering valuable insights when comparing Krystal Biotech to industry peers.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

Krystal Biotech (KRYS) P/E Ratio Historic Data

DateStock priceP/E ratio
Dec 1, 2025$215.1132.26
Nov 3, 2025$197.8529.68
Oct 1, 2025$179.6136.54
Sep 2, 2025$149.0030.31
Aug 1, 2025$156.9831.93
Jul 1, 2025$139.0133.48
Jun 2, 2025$125.3630.19
May 1, 2025$165.6955.45
Apr 1, 2025$174.5858.43
Mar 3, 2025$171.8357.51
Feb 3, 2025$159.0389.96
Jan 2, 2025$156.5088.53

Krystal Biotech (KRYS) End of Year P/E Ratio

DateP/E ratioChange
202642.34+14.49%
202536.98-58.27%
202488.62-204.36%
2023-84.92+457.95%
2022-15.22-31.84%
2021-22.33

FAQs About Krystal Biotech (KRYS) P/E ratio

The latest P/E ratio of Krystal Biotech (KRYS) is 42.34, as of Feb 2, 2026. This is calculated based on its current stock price and earnings per share (EPS).

Krystal Biotech’s last 12-month average P/E ratio is 39.6, compared to its current P/E ratio of 42.34. This reflects a increase of 6.92%.

Krystal Biotech’s current P/E ratio of 42.34 is higher than its last 12-month average P/E of 39.6. A higher P/E can indicate strong future growth expectations, while a lower P/E might suggest undervaluation.

Krystal Biotech’s average P/E ratio over the last 3 years is 153.17. Comparing this to the current P/E helps assess recent valuation trends and whether the stock is trading above or below its mid-term historical range.

Krystal Biotech’s average P/E ratio over the last 5 years is 83.3. A deviation from this historical average may indicate shifts in growth expectations, profitability, or broader market conditions affecting valuation.

Krystal Biotech (KRYS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.